AEON Biopharma (AEON) Free Cash Flow (2021 - 2025)

AEON Biopharma has reported Free Cash Flow for 5 years, with the latest figure at -$4.7 million in Q4 2025.

• Quarterly Free Cash Flow fell 658.78% year-over-year to -$4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$17.3 million (changed 0.14% YoY) and the FY2025 annual result came in at -$17.3 million, up 14.69% from the prior year.
• Free Cash Flow declined to -$4.7 million in Q4 2025 per AEON's latest filing, from -$2.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$158485.0 in Q2 2022 and troughed at -$26.6 million in Q3 2022.
• A 5-year average of -$5.8 million and a median of -$2.6 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 8064.35% in 2022, then jumped 74.24% in 2025.
• Over 5 years, Free Cash Flow stood at -$162633.0 in 2021, then slumped by 5103.74% to -$8.5 million in 2022, then sank by 77.96% to -$15.1 million in 2023, then surged by 95.88% to -$621000.0 in 2024, then plunged by 658.78% to -$4.7 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$4.7 million, -$2.6 million, and -$2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.